Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

D3 Bio

Biotech & Life Sciences · Wuxi, China · Founded 2020 Unicorn

Building a global biotechnology company that develops innovative and more efficacious medicines for patients in need worldwide

Valuation
$1–2.5B
Latest valuation · 2026
Unlock exact value
Headcount
<100
Current team size
Unlock exact value

Investors

8 investors on D3 Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Series B+ 2 investors entered at this stage

Ownership

Who owns D3 Bio

Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.

42% Founders

Some investors are hidden on this public profile. See the full cap table on Dealroom →

Global footprint

Where D3 Bio has talent and traffic

Workforce by country
4 countries with
team presence
🇨🇳 China75.3%
🇺🇸 United States14.8%
🇩🇪 Germany4.9%
🇹🇼 Taiwan4.9%
4 countries shown
Web traffic by country
620 monthly visits
across markets
🇺🇸 United States96.8%
Top 1 markets shown

Talent graph

The shape of D3 Bio's talent

Dealroom maps D3 Bio's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

21 standout operatorsDealroom-flagged across the org
DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock D3 Bio's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$9M patent portfolio · 16 active families

Estimated portfolio value
$9M
0.86% of valuation · 7.7× smaller than top peer Neumora Therapeutics ($66M)
16 active patent families
Where D3 Bio innovates PyrimidineCarcinosisPharmaceutical drugPharmaceutical SubstancesPharmaceutical medicine

Where D3 Bio concentrates vs peers

Each axis is a top-10 topic across D3 Bio and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about D3 Bio

An AI-synthesized read of the highest-engagement posts about D3 Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See D3 Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.